Table 1.
Baseline features of patients with myocardial infarction with type 1 diabetes or without any type of diabetes
| All patients | Matched patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes | No diabetes | Type 1 diabetes | No diabetes | |||||
| Variable | n = 1508 | n = 62,785 | P value | |SMD| | n = 1401 | n = 1401 | P value | |SMD| |
| Age, years (SD) | 61.2 (12.5) | 68.7 (12.8) | < 0.0001 | 0.587 | 61.8 (12.6) | 62.2 (12.9) | 0.255 | 0.035 |
| Men | 59.8% | 65.4% | < 0.0001 | 0.117 | 60.1% | 59.7% | 0.803 | 0.009 |
| Co-morbidities | ||||||||
| Alcohol abuse | 4.8% | 3.1% | 0.0004 | 0.084 | 4.7% | 4.7% | 1.000 | < 0.0001 |
| Atrial fibrillation | 10.3% | 13.1% | 0.002 | 0.085 | 10.6% | 10.3% | 0.803 | 0.009 |
| Cerebrovascular disease | 17.8% | 9.7% | < 0.0001 | 0.225 | 16.4% | 16.3% | 0.957 | 0.002 |
| Chronic pulmonary disease | 11.7% | 12.6% | 0.306 | 0.027 | 12.0% | 12.3% | 0.817 | 0.009 |
| Coagulopathy | 0.3% | 0.4% | 0.774 | 0.008 | 0.4% | 0.2% | 0.480 | 0.027 |
| Dementia | 3.1% | 4.2% | 0.038 | 0.057 | 3.3% | 3.4% | 0.912 | 0.004 |
| Depression | 15.8% | 9.0% | < 0.0001 | 0.207 | 14.7% | 14.6% | 0.956 | 0.002 |
| Heart failure | 33.1% | 15.9% | < 0.0001 | 0.408 | 30.5% | 29.4% | 0.501 | 0.023 |
| Hypertension | 72.5% | 44.0% | < 0.0001 | 0.604 | 70.6% | 69.9% | 0.612 | 0.016 |
| Liver disease | 2.9% | 0.9% | < 0.0001 | 0.145 | 2.5% | 2.7% | 0.714 | 0.013 |
| Malignancy | 10.4% | 11.7% | 0.113 | 0.042 | 10.7% | 11.2% | 0.664 | 0.016 |
| Paralysis | 1.1% | 0.4% | < 0.0001 | 0.084 | 1.1% | 1.1% | 0.853 | 0.007 |
| Peripheral vascular disease | 26.8% | 5.5% | < 0.0001 | 0.605 | 22.9% | 23.1% | 0.875 | 0.005 |
| Prior CABG | 7.9% | 2.7% | < 0.0001 | 0.233 | 6.9% | 6.6% | 0.762 | 0.011 |
| Prior MI | 21.1% | 12.4% | < 0.0001 | 0.234 | 19.7% | 19.8% | 0.921 | 0.004 |
| Psychotic disorder | 3.3% | 2.9% | 0.357 | 0.023 | 3.3% | 3.5% | 0.753 | 0.012 |
| Rheumatic disease | 6.7% | 6.1% | 0.373 | 0.023 | 6.9% | 6.6% | 0.762 | 0.011 |
| Renal failure | 24.3% | 1.9% | < 0.0001 | 0.703 | 18.8% | 19.7% | 0.387 | 0.022 |
| Valvular disease | 5.6% | 5.2% | 0.411 | 0.021 | 5.4% | 6.3% | 0.324 | 0.036 |
| ST-elevation MI | 30.2% | 40.0% | < 0.0001 | 0.205 | 31.3% | 32.7% | 0.363 | 0.031 |
| Anterior* | 53.3% | 46.7% | 0.084 | 0.081 | 53.0% | 50.7% | 0.489 | 0.046 |
| Revascularization | 58.4% | 62.7% | 0.001 | 0.089 | 59.9% | 60.7% | 0.621 | 0.018 |
| PCI | 48.3% | 56.1% | < 0.0001 | 0.156 | 49.8% | 50.0% | 0.934 | 0.003 |
| CABG | 11.1% | 7.3% | < 0.0001 | 0.130 | 11.1% | 11.3% | 0.852 | 0.007 |
| Post-MI medication | ||||||||
| ACEi or ARB | 70.0% | 68.0% | 0.089 | 0.045 | 71.1% | 71.5% | 0.822 | 0.008 |
| Aldosterone antagonist | 5.4% | 3.3% | < 0.0001 | 0.100 | 5.6% | 6.2% | 0.519 | 0.024 |
| Antiarrhythmic | 1.2% | 1.2% | 0.871 | 0.004 | 1.1% | 1.1% | 1.000 | < 0.0001 |
| Beta-blocker | 84.6% | 84.5% | 0.888 | 0.004 | 84.9% | 86.5% | 0.201 | 0.046 |
| Oral anticoagulant | 11.7% | 13.4% | 0.058 | 0.051 | 12.0% | 10.6% | 0.224 | 0.045 |
| P2Y12 inhibitor | 68.4% | 70.0% | 0.176 | 0.035 | 69.2% | 70.3% | 0.485 | 0.025 |
| Statin | 81.8% | 84.2% | 0.012 | 0.064 | 83.3% | 83.9% | 0.264 | 0.042 |
| University Hospital | 55.5% | 51.0% | 0.001 | 0.099 | 55.0% | 54.0% | 0.547 | 0.022 |
| Year of index MI | < 0.0001 | 0.173 | 0.801 | 0.007 | ||||
Features of all patients and propensity score-matched cohort. CABG coronary artery bypass grafting surgery, MI myocardial infarction, PCI percutaneous coronary intervention, SMD standardized mean difference. *Of ST elevation MI patients